ArticleFrontiers in cardiovascular medicine2026
Integrated biomarker model based on cTnI, BNP, and D-dimer for early risk stratification in acute aortic dissection.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early identification of patients at high risk of death following acute aortic dissection (AAD) remains a major clinical challenge because mortality is driven by multiple interacting pathophysiological mechanisms, including myocardial injury, hemodynamic stress, and activation of coagulation pathways. We aimed to develop and internally validate an integrated biomarker-based model for predicting 30-day mortality in patients with AAD. Methods: We conducted a retrospective cohort study to develop and internally validate a multivariable prediction model for 30-day mortality in 572 consecutive patients with AAD. Admission levels of cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), D-dimer, and fibrin/fibrinogen degradation products (FDP) were assessed. Multivariable logistic regression was performed after adjustment for age, Stanford classification, symptom-onset-to-admission time, systolic blood pressure, serum creatinine, and treatment strategy. Model performance was evaluated using discrimination, calibration, net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Internal validation was conducted using bootstrap resampling with 1,000 iterations. Results: Elevated cTnI (adjusted OR = 3.76, 95% CI: 1.87-7.56; Conclusions: An integrated model incorporating cTnI, BNP, D-dimer, and key clinical variables demonstrated good discrimination (optimism-corrected AUC 0.89) and statistically significant incremental value over clinical variables alone (NRI = 0.32, IDI = 0.11). However, the modest AUC improvement (ΔAUC = 0.05) and lack of head-to-head comparison with established risk scores (IRAD, Penn, GERAADA) warrant cautious interpretation and external validation before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.